Thanks to its advanced technology, Genefill dermal fillers have one of the lowest residual BDDE particles in their composition, presenting a toxicity level lower than the more strictest standards around the world.
FDA allowed amount of Residual BDDE (EU) <0.0002 mg
Standards Amount of Residual BDDE (Genefill) <0.0001 mg
Having significantly lower toxicity has successfully demonstrated BDDE as one of the safest cross-linking agents to stabilize the HA-based dermal fillers in the industry.
Additionally, BDDE is also biodegradable making it much preferred for biomedical applications, especially cosmetic products.
*Disclaimer: Before any dermal filler treatment, we recommend asking your doctor about the product, crosslinking agents, and toxicity level.